FindTrial
Sign In

Allergen Specific Cluster Subcutaneous Immunotherapy in Nasobronchial Allergy.

A Study on the Safety and Clinical Efficacy of Allergen Specific Cluster Immunotherapy among patients suffering from Allergic Rhinitis and Allergic Bronchial Asthma.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/03/004487
Enrollment
40
Registered
2014-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients suffering from allergic rhinits and/or bronchial asthma

Interventions

Intervention1: allergic specific subcutaneous Immunotherapy: Modified Allergy Skin testing will be done to identify the individuals who are sensitive to aeroallergens. Individuals who are sensitive fo

Sponsors

KIMS Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Patients between age group 18 â?? 60 years who have Allergic Rhinitis and Allergic Bronchial Asthma and who are sensitive to aeroallergens.

Exclusion criteria

Exclusion criteria: 1. Those who are not willing to take part in the study. 2. Patients with Severe Asthma, Pregnancy, Ischemic Heart Disease, High Blood Pressure, receiving Immunosuppressive medications & Beta-Blockers, and other Immune Disorders.

Design outcomes

Primary

MeasureTime frame
completion of six weeks cluster cycle without adverse outcomes.Timepoint: six weeks—

Secondary

MeasureTime frame
changes in symptom score and medication score at the end of one year. physician evaluation of symptoms of nasobronchial allergyTimepoint: one year—

Countries

India

Contacts

Public ContactDr Chitra nagaraj

KIMS hospital and research centre , bangalore

drchethna@gmail.com9845329145

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026